Heart drug shows promise in prostate cancer fight
NCT ID NCT07311915
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the heart medication propranolol to standard hormone therapy before prostate removal can improve outcomes for high-risk prostate cancer patients. About 30 men will receive the combination treatment for several weeks before surgery. The goal is to see if this approach can eliminate or greatly reduce cancer in the removed prostate tissue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongda Hospital
Nanjing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?